INFINITY PHARMACEUTICALS, INC. Form 8-K

June 04, 2013

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

PURSUANT TO SECTION 13 OR 15(d)

OF THE SECURITIES EXCHANGE ACT OF 1934

Date of Report (Date of earliest event reported): June 2, 2013

Infinity Pharmaceuticals, Inc.

(Exact name of registrant as specified in charter)

Delaware (State or other jurisdiction


000-31141 (Commission File Number) 33-0655706 (IRS Employer

of incorporation)

Identification No.)

Edgar Filing: INFINITY PHARMACEUTICALS, INC. - Form 8-K

780 Memorial Drive, Cambridge, MA 02139
(Address of principal executive offices) (Zip Code)
Registrant s telephone number, including area code: (617) 453-1000



- " Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- " Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- " Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Edgar Filing: INFINITY PHARMACEUTICALS, INC. - Form 8-K

Item 8.01. Other Events

On June 2, 2013 and June 3, 2013 we issued press releases announcing new data from our ongoing Phase 1, open-label, clinical trial of IPI-145, our potent, oral inhibitor of phosphoinositide-3-kinase (PI3K)-delta and PI3K-gamma, in patients with advanced hematologic malignancies. A copy of each of these press releases is filed as Exhibits 99.1 and 99.2, respectively, and is incorporated herein by reference.

Item 9.01. Financial Statements and Exhibits.

(d) The following exhibits are included in this report:

| Exhibit No. | Description |
|----------------|--|
| 99.1 | Press release dated June 2, 2013, entitled Infinity Reports Updated Phase 1 Data Showing Encouraging Clinical Activity of IPI-145 in Chronic Lymphocytic Leukemia at ASCO Annual Meeting. |
| 99.2 | Press release dated June 3, 2013, entitled Infinity Reports Updated Phase 1 Data Showing Encouraging Clinical Activity of IPI-145 in B-Cell and T-Cell Lymphomas at ASCO Annual Meeting and Announces Initiation of Phase 2 Clinical Study in Indolent Non-Hodgkin Lymphoma. |

Edgar Filing: INFINITY PHARMACEUTICALS, INC. - Form 8-K

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

INFINITY PHARMACEUTICALS, INC.

Date: June 3, 2013 By: /s/ Lawrence E. Bloch

Lawrence E. Bloch, MD, JD

EVP, Chief Financial Officer and Chief Business Officer